• Monday, April 11, 2022 @ 12:00 am

FY 2021 results exceeded guidance, reflecting strong Cresemba growth, resulting in an operating profit. Basilea will focus on anti-infectives and accelerate its path to sustained profitability guided from 2023 onwards. Oncology will be exited through asset transactions in 2022. Key catalysts include:

  • Strategic transactions oncology pipeline (during 2022)
  • Topline results phase III “ERADICATE” trial of Zevtera in bacteremia (mid-2022)
  • US filing of Zevtera for severe bacterial infections (H2 2022)

Read the full Basilea Valuation Report 

You may also be interested in